"Since many patients with type 2 diabetes will eventually require insulin, it is important to assess a compound's ability to be used in combination with insulin to manage blood glucose control over the long term," said Anthony Barnett, MD, University of Birmingham and Heart of England NHS Foundation Trust and principal investigator of the study. "This is the first longer-term study to report that ONGLYZA 5 mg, used with insulin, maintains improvement in glucose control over 24 to 52 weeks in adult patients with type 2 diabetes."
In Europe, ONGLYZA is indicated as a once-daily 5 mg oral tablet dose in adult patients with type 2 diabetes mellitus to improve glycemic control:
- in combination with metformin, when metformin alone, with diet and exercise, does not provide adequate glycemic control;
- in combination with a sulphonylurea, when sulphonylurea alone, with diet and exercise, does not provide adequate glycemic control in patients for whom use of metformin is considered inappropriate; or
- in combination with a thiazolidinedione, when the thiazolidinedione alone, with diet and exercise, does not provide adequate glycemic control in patients for whom use of a thiazolidinedione is considered appropriate.
ONGLYZA is currently not indicated in combination with insulin therapy.
Source Bristol-Myers Squibb and AstraZeneca